Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out the maximum tolerated dose (MTD) of the combined
therapy of lenalidomide (Revlimid®) and Granulocyte/macrophage colony stimulating factor and
CD40 Ligand expressed in the K562 cell line (GM.CD40L) bystander vaccine. This research is
also being done to see how well the combination of these drugs works to fight myelodysplastic
syndrome (MDS).
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute